Cingulate Inc. (NASDAQ:CING – Get Free Report)’s share price rose 0.8% during trading on Monday . The company traded as high as $0.94 and last traded at $0.89. Approximately 72,593 shares were traded during trading, a decline of 77% from the average daily volume of 320,454 shares. The stock had previously closed at $0.88.
Analyst Ratings Changes
Separately, HC Wainwright upped their target price on Cingulate to $8.00 and gave the company a “buy” rating in a report on Friday, January 5th.
View Our Latest Report on Cingulate
Cingulate Stock Down 1.0 %
Institutional Trading of Cingulate
A hedge fund recently bought a new stake in Cingulate stock. Commonwealth Equity Services LLC purchased a new stake in shares of Cingulate Inc. (NASDAQ:CING – Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 100,771 shares of the company’s stock, valued at approximately $71,000. Commonwealth Equity Services LLC owned about 0.64% of Cingulate at the end of the most recent reporting period. Institutional investors and hedge funds own 41.31% of the company’s stock.
Cingulate Company Profile
Cingulate Inc, a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults.
Recommended Stories
- Five stocks we like better than Cingulate
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- High-Yield Texas Instruments Could Hit New Highs Soon
- Most Volatile Stocks, What Investors Need to Know
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 3 Fintech Stocks With Good 2021 Prospects
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.